Pharma BD Deal Intelligence
A deal Wall Street panned as reckless overpayment delivered Humira — pharma's best-selling drug in history, generating over $200B in cumulative sales and spinning off AbbVie.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
BASF sold its Knoll pharmaceutical business to Abbott for $6.9B cash; Abbott CEO Miles White cited 'significant synergies' and an 'excellent strategic fit' as…
Adalimumab was the first fully human monoclonal antibody approved by the FDA (2002) and became the largest selling pharmaceutical product worldwide from…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Abbott acquired BASF's pharmaceutical unit Knoll for ~$6.9B cash; brought in D2E7/adalimumab (later Humira) plus Synthroid, Mavik. Closed 2001-03.
A deal Wall Street panned as reckless overpayment delivered Humira — pharma's best-selling drug in history, generating over $200B in cumulative sales and spinning off AbbVie.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) (this deal) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| Abbott Laboratories / St. Jude Medical | 2016 | $30.5B | 82 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
| Abbott Laboratories / Genentech, Inc. (Roche Group) | 2007 | — | 79 |
← Browse all deals · How we score deals
More: 2001 deals · Abbott Laboratories deals